Registry Experience at the Washington Hospital Center, Des - Taxus Liberte Versus Xience V

Medstar Health Research Institute1,200 enrolled

Overview

Multicenter, retrospective registry to collect 9-12 month follow-up data to evaluate major adverse cardiac events in patients whom have undergone percutaneous coronary intervention and received either Taxus Liberte or Xience V.

Study Type

OBSERVATIONAL

Enrollment

1,200

Conditions

Coronary Artery Disease

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients 18 years of age or older, both genders * Underwent PCI with Taxus Liberte (alone) or Xience (alone) Exclusion Criteria: * Underwent PCI with a non-Taxus Liberte or Xience V DES during the same procedure * Received both Taxus-Liberte and Xience-V during the same index procedure * Patients not taking, or unable to take, dual antiplatelet therapy (aspirin plus clopidogrel or prasugrel).

Locations (10)

Washington Hospital Center

Washington D.C., District of Columbia, United States

Midwest Cardiovascular Research Foundation

Davenport, Iowa, United States

Iowa Heart Center

West Des Moines, Iowa, United States

Outcomes

Primary Outcomes

Major adverse cardiac events,

A composite of all-cause death, Q-wave myocardial infarction, and target vessel revascularization

Time frame: 1 year

Secondary Outcomes

Stent thrombosis

Time frame: 1 year

Target vessel revascularization

Time frame: 1 year

Cardiac death

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.